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ABSTRACT
Randomized controlled clinical trials (RCTs) are consi-
dered to be the gold standard for evidence-based medi-
cine nowadays, and are important for directing medical 
practice through consistent scientific observations. Steps 
such as patient selection, randomization and blinding 
are fundamental for conducting a RCT, but some addi-
INTRODUCTION
Randomized controlled clinical trials (RCTs) are 
considered to be the gold standard for evidence-based 
medicine today(1-3). They have the aim of creating a 
basis for supporting the use of one therapeutic me-
thod or another by means of analyzing different in-
terventions, or through comparing interventions with 
placebo. Evidence-based medicine thus has the objec-
tive of directing medical conduct through consistent 
scientific observations. 
The level of evidence in clinical studies can be 
classified in the following manner, ordered from the 
lowest to the highest level: case reports, case-control 
studies, prospective observational studies and RCTs. 
The main problems in observational studies are selec-
tion bias and lack of a control group. In this respect, 
the main advantage of RCTs is precisely the randomi-
zation, which diminishes the chances of “confounder” 
effects and selection bias.
For clinical trials to have the potential to suggest 
to physicians that a certain therapeutic method is the 
one most indicated in a given situation, they need to 
present internal and external validity. In fact, studies 
have to answer two essential questions posed by clini-
cians: “are the results valid?” (which can be assessed 
through the internal validity of the study); and “are 
the results applicable to my patient?” (which can be 
assessed through the external validity of the study). 
If a study presents internal validity, this means that 
the study design was appropriate for answering the 
question posed in relation to the sample studied. In 
turn, external validity implies the potential for the 
results from that trial to be extrapolated to other po-
pulations, i.e. such that the results are valid not only 
for the participants in that study, but also for others(4). 
Possessing adequate internal validity is a condition 
sine qua non for possessing external validity: in other 
words, methodological problems that affect the study 
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surgical procedures, as is common in orthopedics. The 
aim of this article was to highlight and discuss some 
difficulties and possible limitations on RCTs within the
field of surgery.
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itself make it impossible for its results to be extrapo-
lated, since these results may not be valid even for 
the sample studied(5). 
Designing a perfect study with minimal bias may 
not be feasible, because this may make it unviable 
to carry out the study (for example, through grea-
tly increasing the cost or the number of individuals 
that would have to be included). For this reason, for 
most studies, a balance has to be sought between
feasibility and methodological rigor, with a design in 
which great care is taken to avoid errors that might 
invalidate the study internally. Steps such as patient 
selection, randomization and blinding are fundamen-
tal and give rise to certain additional difficulties in 
trials that involve surgical procedures, as is common 
in orthopedics. The aim of this paper was to highlight 
and discuss some difficulties and possible limitations 
of RCTs within the field of surgery. 
DIFFICULTIES AND LIMITATIONS
Design and initial question
The design of any study should be chosen based on 
a specific question that corresponds to the problem to 
be investigated. A very broad initial question makes 
it difficult to calculate the sample size and choose 
the outcome variables. For example: what is the re-
sult from uncemented total knee arthroplasty? If the 
question is more specific, this helps to delineate the 
study design: “Does the functional result over the 
first year after total knee arthroplasty differ between 
uncemented and cemented procedures?” In the initial 
question, the population of interest, primary outcome, 
length of follow-up until the primary outcome and the 
comparison group should be defined.
Some study designs present limitations in sur-
gical trials. For example, crossover designs cannot 
be implemented. In studies within orthopedics, the 
intervention is often permanent and there is no “wa-
shout” as occurs with use of medications. In addition, 
patients cannot be used as their own controls for two 
successive interventions in the case of single organs. 
In the case of double organs (surgery on both knees, 
for example), patients at the time of the second in-
tervention are not the same as at the time of the first 
intervention, because they enjoy the benefits from the 
previous intervention. However, one possible design 
consists of comparing effects between double organs 
if the level of disease is similar, which rarely occurs.
Furthermore, it needs to be emphasized that the use 
of placebo groups in surgical trials frequently presents 
significant ethical limitations, and this may even be 
impossible to implement(6). 
Sample calculation
Another important limitation that surgical trials 
frequently present consists of the small numbers of 
cases studied and its consequent implication for the 
statistical power of the study. The power of a study 
depends on the sample size, the homogeneity of the 
sample, the homogeneity of the results (standard de-
viation of the results) and the differences between the 
means of the results in each group. In surgical studies, 
it is often difficult to reach the minimum number of 
patients (sample size) needed to attain a statistical 
power of 80%, the percentage that is considered to be 
the minimum acceptable in most clinical trials. This 
occurs for a variety of reasons: the cost of the study 
(usually higher when surgical procedures are invol-
ved) may make it unviable to reach the ideal number; 
the low frequency of some pathological conditions 
and consequently of surgical procedures on these con-
ditions; and difficulties in calculating what the ideal 
sample size should be, especially when new surgical 
procedures are involved, because of the imprecision 
in estimating the magnitude of the treatment effect; 
among others. As an example, Freedman et al(7) sho-
wed that only 9% of orthopedic trials included an a 
priori calculation of the sample size. 
In this light, proposals to conduct multicenter trials 
are often made, with the aim of expanding the num-
bers of individuals. In such situations, bias relating to 
standardizing the intervention may arise. It is difficult 
to affirm that surgical interventions made by different 
centers are the same, given that there is variability 
between surgeons and many other variables are inclu-
ded. For example, there are the types of anesthesia, 
differences in anesthesia equipment, differences in 
surgical equipment, the methods of sterilizing surgical 
materials, the nursing team’s expertise in postopera-
tive care, the organization of the team at the surgical 
center (thus influencing the duration of surgical pro-
cedures), differences in the availability of technolo-
gy (such as the quality of technological equipment 
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for radioscopy and microscopy) and differences in 
the bacterial flora between hospitals, among various 
other factors (both detectable and undetectable) that 
influence the final result. It may even be argued that 
these biases would influence both arms of the stu-
dy, and would be diluted with increasing numbers of 
individuals. This may be true in some cases, but it 
may generate an inverse effect in others, when certain 
factors cause bias in only one of the arms (use of ra-
dioscopy, when necessary in only one of the surgical 
techniques studied, for example). Moreover, in ca-
ses in which increases in the numbers of individuals 
may dilute all this variance, an enormous sample is 
needed, thus implying a study of dimensions that are 
often impracticable from a financial point of view. On 
the other hand, RCTs with large samples are gene-
rally sponsored by the industry and are conducted by
researchers with links to these companies, which
creates conflicts of interest and considerably increases 
the risk of bias(8, 9).
On the other hand, increasing the heterogeneity of 
a study will increase its external validity. In fact, one 
of the factors that explain the extremely favorable 
results seen in some small studies within orthopedics 
may be the presence of excellent conditions at the 
place where the study was conducted that would be 
difficult to reproduce in other locations. 
One other important point is that even if studies 
present low power, they may be valuable when aggre-
gated in meta-analyses. Likewise, such studies may 
supply preliminary data for calculating sample sizes 
and assessing the feasibility of conducting similar 
studies in the future.
It needs to be emphasized that calculating the sam-
ple size should always be done before starting the 
study: it should never be done subsequently or with 
the aim of validating the result. 
Type I error
Type I error (or alpha error) consists of concluding 
that a difference exists between the study groups when 
in reality it does not exist (also called a false positive). 
It is usually considered acceptable for the chance that 
this error could occur to be up to 5%. One common 
cause of this error comes through carrying out many 
statistical tests on different hypotheses, until finding a 
positive result. The best way to avoid this situation is 
to define in advance what statistical test will be used 
at the end of the study, along with the main question 
of the study, thereby minimizing the number of tests 
for the primary outcome. Another situation that may 
favor this error is to use multiple outcomes with many 
variables, which increases the final number of tests. 
However, for secondary outcomes, the number of tests 
does not influence the type I error of the study.   
In surgical RCTs, it is common to use several 
outcome measurements, given that the results from 
a surgical procedure can be analyzed in different 
manners: pain scales, functional scales, quality-of- 
life scales, satisfaction scales and complementary 
examination scales. Once again, the study design 
should be directed towards answering just one speci-
fic question. The other outcomes should be analyzed 
as secondary outcomes.
Type II error
Type II error consists of concluding that there is no 
difference between the study groups when in reality a 
difference exists (false negative). By convention, the 
limit for occurrences of this error is generally set at 
a chance of 20% (in order words, a study power of 
80%). The causes of type II error include insufficient 
numbers of patients in the study, generally because 
of lack of sample size calculation or error in this cal-
culation, or difficulty in obtaining sufficient numbers 
of subjects, as discussed above. In a review of the 
literature on orthopedic trauma, Lochner et al(10) sho-
wed that the incidence of this problem was 90.52% 
among a total of 117 randomized studies evaluated. In 
small studies, in which the researchers conclude that 
there is a high possibility of type II error, one solution 
is to increase the homogeneity of the study through 
diminishing the variance and increasing the power of 
the study. However, this measure reduces the external 
validity of the study.
Intention to treat
In clinical trials, it is suggested that the analysis 
on the data obtained should be done based on the 
group for which the patient was selected. This prin-
ciple is called intention-to-treat analysis. This method 
for assessing the results makes it possible to protect 
the randomization, which is a fundamental point in 
relation to RCTs. 
In surgical trials, following this principle may ge-
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nerate strange or even incongruent responses, depen-
ding on how this method is applied. For example, 
a patient drawn for non-surgical treatment who, for 
any reason, then undergoes surgical treatment should, 
according to the intention-to-treat principle, still be 
analyzed as a non-surgical case. If this patient ha-
ppens to present infection at the surgical site, the 
results from such a study would show “occurrence 
of infection of the surgical site” as a “complication 
from non-surgical treatment”. Hence, the intention- 
to-treat principle should be applied using data prior 
to performing the rescue surgery, or else the results 
will be biased. 
Although drop-outs are a frequent problem in clini-
cal research, this problem is different in orthopedics, 
since the intervention is generally applied fully to 
the patients (thus differing from studies on drugs, in 
which the patients can drop out at any time, from the 
beginning to the end of the study). In this respect, 
studies within orthopedics present an additional ad-
vantage. Investigators in this field should therefo-
re undertake frequent measurements if there is any
drop- out or crossing of treatments.
In a recent study, Herman et al(11) observed that 
only 16.4% of RCTs within orthopedics between 2005 
and 2008 had adequately applied this principle. Most 
of these studies had excluded the patients lost du-
ring the follow-up, from the final statistical analysis. 
This was notably done in trials that involved surgical 
procedures. Omission of these data may lead to bias, 
because it affects the integrity of the randomization. 
External validity
When extrapolation of the results from a clinical 
trial is desired, the premise taken is that the interven-
tion undertaken or that is intended will be the same 
at all locations or for all physicians in different loca-
tions. This is because both the formula of the drug and 
its pharmacokinetics and pharmacodynamics are the 
same, regardless of who is prescribing it. The problem 
is that the external validity of RCTs is often low. This 
occurs in surgical trials for three basic reasons: the 
surgeon, the environment or the patient.
Interventions made by one surgeon are not ne-
cessarily identical to those made by another. That 
is, no matter how reproducible a technique is, it is 
not identical. Moreover, new surgical techniques 
generally depend on a learning curve, and this may 
vary for each technique and for each surgeon. In 
this way, even for the same surgeon, operations per-
formed at different times may differ significantly. 
Thus, results from a surgical technique obtained by 
one group of authors may be different from those 
obtained by others, without implying methodological 
failings or random effects but, rather, as a result of 
the fact that the interventions are not identical. This 
unmeasurable phenomenon may imply that there is a 
limitation to the external validity of surgical studies, 
especially for results that are produced by one or just
a few surgeons. 
The environment of a teaching hospital, where 
many studies are conducted, also may not be represen-
tative of the general population. Furthermore, patients 
participating in studies tend to receive differentiated 
attention in relation to ordinary patients. Finally, the 
patients who agree to enter such studies and those 
who fit within the often restrictive inclusion criteria 
may not be representative of the general population. 
Nonetheless, the particular features of surgical 
trials as described above do not justify avoidable 
methodological failures. As reported by Ahmad et 
al(12), in a study on osteoarthrosis of the hip and knee, 
researchers failed to describe details about their stu-
dy. While the surgical procedure used was described 
in all studies, the pre and postoperative care and the 
anesthesia used were described in only 7%, 50% and 
13%, respectively. Lack of information of this nature 
seriously compromises the generalization of the data 
and, consequently, the external validity.
Recruitment
The acceptance rate for participation in a surgi-
cal RCT is generally less than 50%, and the main 
reasons for not participating that patients give are 
their preference for one of the arms of the treatment, 
their discontent with the randomization and the pos-
sibility of higher expenses(13). New and experimental 
surgical procedures cause patients to be anxious and 
apprehensive to a greater extent than if they were 
faced with a new medication. This may be because 
although most people have already taken some form 
of medication during their lives, most of them have 
never been through surgery. It may also be because 
of real worry about sequelae caused by unsuccessful 
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surgery. Thus, recruitment of subjects for surgical trials 
is more difficult, which increases the study period re-
quired and often forces the sample size downwards. Al-
though there is no ideal way to deal with this difficulty, 
conducting the study with linkage to large renowned 
institutions may stimulate acceptance. Small variations 
in established techniques or use of new surgical pro-
cedures to treat pathological conditions for which no 
effective treatment exists may also stimulate people 
to enter the study. No information on risks or existing 
evidence should ever be omitted from the free and in-
formed consent statement, which it is mandatory for all 
patients to sign before entering the study, as required 
by the institutional ethics committees. 
Another important problem regarding recruitment 
is selection bias. Patients who agree to participate 
in the study may have characteristics differing from 
those who are receiving treatment at a clinical cen-
ter. Within this context, it is important that the group 
that did not agree to participate in the study should 
be compared with the group that did agree to this. If 
there are differences in any factors, these should be 
included in a covariance analysis. 
Randomization
The random nature of patients requires that both 
surgical techniques should be performed with obser-
vance of randomization. Any limitation on carrying 
out one of the techniques (only on certain days of the 
week, only by a certain surgeon, etc) implies a risk of 
harming this principle. For example, in cases of emer-
gency or trauma, in which the procedure is complex 
and is done by a particular surgeon, the randomization 
would be subject to the availability of the physician 
and thus allocation according to convenience would 
be required, thereby impairing the randomization.
When the study involves comparison between 
different implants, further difficulties arise. Ideally, 
the draw should be made at the time of the surgery. 
However, there are operational and financial disad-
vantages in this, resulting from transportation and 
sterilization of the materials, especially in the case of 
implants supplied as a batch, when they do not form 
part of the hospital’s arsenal (both of the implants 
under examination should be available and sterilized 
within the operating room). On the other hand, if the 
draw is done earlier, there is a considerable risk of 
loss of blinding, given that a series of individuals 
(in the materials center and nursing team) will know 
which group the subject is in. Furthermore, if the 
surgeon’s blinding is removed, he could introduce 
bias, even if unconsciously. 
Another difficulty in the randomization occurs 
when inclusion of a given patient can only be defined 
after intraoperative evaluation. For example, in a study 
on meniscal sutures, the patient can only be included 
in the study if the suture is possible. Thus, the team 
needs to be prepared to perform randomization during 
the operation or to use a preoperative randomization 
method that does not create imbalance between the 
groups if a patient is excluded during the operation.
Among the RCTs within orthopedics that were pu-
blished between 1988 and 2000, only 41% presen-
ted randomization that was appropriate, according to 
Bhandari et al(14).
Protection of randomization (concealment)
The randomization methods that are most used 
(sealed envelopes and lists generated using compu-
ter software) are susceptible to bias. Regarding sealed 
envelopes, they should be sealed in such a way that 
opening them without tearing them is impossible, and 
should be made of opaque material such that seeing 
through the envelope by holding it up to the light is 
impossible(1). Lists generated using software need to be 
kept protected by the principal researcher throughout 
the study period, under the care of someone who is not 
participating in the trial. The ideal methods for protec-
ting the randomization list would be those provided by 
outsourced companies that are available 24 hours a day, 
on the internet or by telephone. Use of dates of birth 
or hospital registration numbers are not considered to 
be valid forms of randomization, not are lists that are 
open for everyone to read.
As stated above, to protect the randomization 
in trials that compare two surgical procedures, it 
should preferably be done inside the operating thea-
ter, after anesthesia, thus diminishing the chance of 
unmasking the preoperative data-gathering and the 
patients themselves.
Blinding
Blinding or masking is an important part of con-
ducting RCTs, in order to minimize bias. Double-blind 
studies (both the patient who receives the intervention 
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and the physician or the researcher conducting the 
study are blinded) are the type of RCT most used. 
Sometimes a triple-blind design is suggested (with 
additional blinding for the person who analyzes the 
data and the person who writes the text)(15). These 
terms may cause confusion for readers, and the re-
commendation that is currently most accepted is that 
descriptive reports on who was blinded in the study 
should be provided(16).
Blinding in non-pharmacological trials has already 
been shown to be more laborious than in pharmaco-
logical trials, in a comparative study by Boutron et 
al(17). The difficulties relating to blinding in RCTs that 
involve interventions relating to surgical procedures 
are described below. 
a) Blinding of the surgeon
Two situations may be presented: studies compa-
ring two surgical interventions and studies comparing 
a surgical intervention with non-surgical treatment.
For the surgeon who performs the operation, if 
the operative techniques differ (because of different 
access routes or implants), blinding is impossible(18). 
It could be argued that if the postoperative data ga-
thering was blinded, a source of bias would be mini-
mized, but if the surgeon believes more in one of the 
techniques, he might make greater efforts towards 
this one, thus inducing randomization errors. If the 
operative technique is identical, and the intervention 
consists of introducing an additional factor (injection 
of growth factor, postoperative medication, use of 
a new suture, etc), blinding may be possible, even 
for the surgeon, provided that the intervention allo-
ws blinding with a placebo or has the same physical 
characteristics as the control.
If the study involves a non-surgical group, obviously 
it is not possible for the surgeon to be blinded.
It needs to be emphasized that in studies in which 
the surgeon is not blinded, some data gathered during 
the surgical procedure (for example, the volume of 
bleeding) are subject to data-gathering bias.
b) Blinding of the patient
This form of blinding is very difficult to achieve in 
comparisons between surgical and non-surgical treat-
ments, for obvious reasons. 
When the aim of the study involves comparison 
between two different surgical techniques, there is a 
new difficulty when the access routes are different. 
During the follow-up, if the patient has access to the 
radiographic examinations (which usually occurs), 
differences between the implants used may also be 
noticed and, in this way, the reliability of the data to 
be analyzed may be altered. 
Studies with practically “perfect” blinding 
of patients do exist, like the study described by 
Moseley et al(19). In this clinical trial on the efficacy 
of knee arthroscopy for treating osteoarthrosis of 
the knee, three groups were evaluated: arthroscopic 
debridement, simple lavage of the joint and placebo 
surgery in which only the skin incisions were made 
(sham surgery). The placebo group watched a video 
simulation of the surgery during their procedure. 
However, the ethical implications of studies like this 
are evident, and it is rare to obtain approval for such 
studies from research ethics committees and from 
patients(20, 21). It needs to be borne in mind that if 
such a study has any blinding problem at other stages 
(such as in relation to allocation or data gathering), 
placebo surgery will become completely anti-ethical. 
Moreover, it should be remembered that surgery does 
not consist of just an incision and skin suturing. 
If the surgery generates other signs (such as joint 
effusion or hematoma, etc) during the postoperative 
period, the blinding may be compromised and 
placebo surgery (just an incision, for example) may
not be justified.
If there is difficulty with blinding, the research 
group should consider alternative solutions, such 
as the use of objective outcomes (like laboratory
measurements) or short-term outcomes in which it is 
more feasible to have the patient blinded for a shorter 
period, for example during the hospital stay.
c) Blinding of the assessor
The independent assessor, who is generally a phy-
sician or physiotherapist who is not participating di-
rectly in the study, is an important player in RCTs 
within orthopedics. Functional scales, which are used 
in virtually all studies of this type, are applied by this 
assessor. The assessor may present loss of blinding, 
especially if the procedures under evaluation are car-
ried out using different access routes, which gives 
rise to surgical scars that lead to identification of the 
group. Masking the scar in all the evaluation, through 
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the use of appropriate clothing, is one way to ensure 
this principle, but in daily practice this may not be 
achieved, especially during physiotherapy sessions. 
When different surgical techniques require diffe-
rent rehabilitation protocols, the blinding may again 
be lost if the physiotherapist who is in attendance at 
the regular sessions is the same one who applied the 
functional scales.
In a systematic review, Poolman et al(22) observed 
that only 50% of the RCTs within orthopedics imple-
mented this form of blinding. In addition, they sho-
wed that the effect of the treatment was significantly 
greater in the studies without blinding thereby making 
it clear that assessment bias was present. 
d) Blinding of the data assessor 
This blinding is the simplest type to obtain. It is 
enough for the results spreadsheet not to contain a 
description of the group to which the patient belongs, 
but only numbers, and it can be achieved in virtually 
all RCTs. However, no article published in an ortho-
pedics journal cited this method between the years 
1988 and 2000, according to Bhandari et al(14).
Adherence
Differing from the various clinical conditions that 
require continual regular checks over long periods, and 
possibly throughout the patient’s life, such as in cases 
of hypertension or diabetes, orthopedic interventions 
are often “curative”. Acute conditions (fractures) and 
even chronic conditions (osteoarthritis undergoing
arthroplasty, for example) present significant im-
provement of symptoms over the short and medium
terms and, in the absence of complications, it may be 
difficult to keep up the follow-up for a long period, 
thus giving rise to loss of subjects.
Another difficulty relating to patient adherence to 
orthopedic surgical protocols is the need for reha-
bilitation. Taking a pill at home demands less from 
patients than does leaving home and traveling to the 
physiotherapy location, when the patient is in pain 
after undergoing surgery. Since lack of adequate reha-
bilitation or dropping out from rehabilitation is often 
an exclusion criterion of the study, this may compro-
mise the final result from the surgery. Therefore, this 
problem should be borne in mind when developing 
the protocol. Facilitating and simplifying the posto-
perative procedures as much as possible stimulates 
better patient adherence.
FINAL REMARKS
RCTs have excellent application for assessing new 
medications. Today, for a new medication to be ap-
proved by the United States Food and Drug Admi-
nistration (FDA)*, it has to go through assessments 
at several levels (studies on animals, safety analysis 
and clinical studies). Before regularization of the pro-
duct, so-called phase III studies involve thousands of 
patients in a randomized manner. Even after the drug 
has been made commercially available, monitoring 
of even bigger patient samples continues. In the case 
of surgical interventions, there is no standardization 
of specific rules for their approval, and RCTs are not 
required for a given surgical technique to be incor-
porated into clinical practice. It is usually enough to 
have case series showing good clinical results, for the 
technique to be put into use.
RCTs present various advantages, especially with 
regard to diminished bias in data gathering and analy-
sis, thus justifying their great prestige within medical 
research. However, the limitations and difficulties in 
applying their principles to studies within the field 
of surgery are far from few. These particular features 
give rise to disadvantages when seeking to publish in 
general medical journals, where the competition for 
editorial space is fierce.
One important point is that many of the difficulties 
in conducting RCTs can be resolved through alterna-
tive solutions, like some that have been discussed in 
this paper. In other cases, researchers should be aware 
of the limitations and assess whether the data gathe-
red will be valid. It is worth emphasizing that open 
observational studies are also important, especially at 
the initial stages of testing a new intervention. Howe-
ver, in such cases, well-designed data analysis techni-
ques are fundamentally important, with construction 
of multivariate regression models and controls for 
potential confounding factors.
Concluding, orthopedists should prioritize conduc-
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ting RCTs whenever feasible. Although knowledge 
derived from other study designs that are considered 
to present a lower level of evidence (case-control, 
cohort, case series, descriptions of techniques and 
specialists’ opinions) is also important, the bias pre-
sent in these studies and the validity of their results 
should be interpreted critically and, if possible, should 
be analyzed together with the results from RCTs.
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